Retension Pharmaceuticals (RTSN) Stock Analysis

What Retension Pharmaceuticals does

Retension Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Its product, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. The company was founded by Eric Keller and Paul Sweetnam in 2023 and is headquartered in Falls Church, VA.

Key metrics

ETFs linked to RTSN

Broad-market and Healthcare sector ETFs an investor holding Retension Pharmaceuticals is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RTSN fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Retension Pharmaceuticals?

Retension Pharmaceuticals trades under the ticker RTSN on NASDAQ.

Which exchange is RTSN listed on?

RTSN is listed on NASDAQ.

What sector does Retension Pharmaceuticals operate in?

Retension Pharmaceuticals is classified in the Healthcare sector (Medical - Pharmaceuticals industry).

How can PortView help analyze RTSN in a portfolio?

PortView shows RTSN's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.